U.S. Blood-Based Biomarker for Parkinson’s Disease Market Size, Share, Industry Analysis Report By Biomarker Type [Alpha-Synuclein (a-syn), Neurofilament Light Chain (Nfl)], By Application, By Technology Platform, By End User – Market Forecast, 2025–2034
Description
The U.S blood-based biomarkers for Parkinson’s disease market size is expected to reach USD 1,156.34 million by 2034, according to a new study by Polaris Market Research. The report “U.S. Blood-Based Biomarker for Parkinson’s Disease Market Share, Size, Trends, Industry Analysis Report By Biomarker Type [Alpha-Synuclein (α-syn), Neurofilament Light Chain (Nfl)], By Application, By Technology Platform, By End User; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Blood-based biomarkers for Parkinson’s disease refer to measurable biological molecules in the blood that aid in the early detection, diagnosis, and monitoring of disease progression and therapeutic responses. The U.S. blood-based biomarker for Parkinson’s disease market is driven by the increasing focus on noninvasive diagnostic alternatives that offer improved patient compliance and reduce reliance on imaging techniques or cerebrospinal fluid analysis. This shift toward minimally invasive approaches is encouraging the development of highly sensitive and specific biomarker panels capable of identifying Parkinson’s Disease in its preclinical stages, ultimately enabling earlier therapeutic intervention and improved disease management outcomes.
The growing integration of advanced omics technologies, such as proteomics and transcriptomic, into biomarker discovery workflows drives the expansion opportunities. These technologies are enhancing the identification of novel blood-based markers by enabling high-throughput screening and multi-dimensional data analysis. Omics-based insights are playing a crucial role in expanding the biomarker landscape and fostering the development of personalized diagnostics and treatment strategies tailored to individual patient profiles, as research continues to deepen the understanding of Parkinson’s disease pathology.
U.S. Blood-Based Biomarker for Parkinson’s Disease Market Report Highlights
In terms of application, the diagnostic biomarkers segment led revenue generation and was valued at USD 81.60 million in 2024, owing to their critical role in detecting Parkinson's during early/prodromal stages when intervention is most impactful.
Based on biomarker type, the NfL biomarker segment is projected to record the highest CAGR of 19.50% during the forecast period, owing to its established utility as a sensitive neurodegeneration indicator across multiple neurological disorders.
In terms of technology platform, the αSyn-SAA segment held a notable market share in 2024 due to its high sensitivity and specificity in detecting misfolded alpha-synuclein aggregates.
Based on end user, the pharmaceutical companies segment is projected to grow significantly during 2025–2034, driven by rising investments in disease-modifying therapies and personalized treatment development.
A few global key market players in the U.S. blood-based biomarker for Parkinson’s disease market include Abbott Laboratories, Alamar Biosciences, Amprion, Biogen, C2N Diagnostics, Denali Therapeutics, Quanterix Corporation, SomaLogic, Thermo Fisher Scientific Inc., and Verily Life Sciences
Polaris Market Research has segmented the U.S. blood-based biomarker for Parkinson’s disease market report on the basis of biomarker type, application, technology platform, and end user:
By Biomarker Type Outlook (Revenue, USD Million, 2020–2034)
Alpha-Synuclein (α-Syn)
Neurofilament Light Chain (NfL)
Inflammatory Markers
Metabolic Biomarkers
Others
By Application Outlook (Revenue, USD Million, 2020–2034)
Diagnostic Biomarkers
Prognostic Biomarkers
Monitoring Biomarkers
Therapeutic Response Biomarkers
Others
By Technology Platform Outlook (Revenue, USD Million, 2020–2034)
Alpha-Synuclein Seeding Amplification Assay (αSyn-SAA)
ELISA-Based Assays
Immunoassays
Mass Spectrometry
Others
By End User Outlook (Revenue, USD Million, 2020–2034)
Hospitals and Clinics
Diagnostic Laboratories
Research Institutes
Pharmaceutical Companies
Blood-based biomarkers for Parkinson’s disease refer to measurable biological molecules in the blood that aid in the early detection, diagnosis, and monitoring of disease progression and therapeutic responses. The U.S. blood-based biomarker for Parkinson’s disease market is driven by the increasing focus on noninvasive diagnostic alternatives that offer improved patient compliance and reduce reliance on imaging techniques or cerebrospinal fluid analysis. This shift toward minimally invasive approaches is encouraging the development of highly sensitive and specific biomarker panels capable of identifying Parkinson’s Disease in its preclinical stages, ultimately enabling earlier therapeutic intervention and improved disease management outcomes.
The growing integration of advanced omics technologies, such as proteomics and transcriptomic, into biomarker discovery workflows drives the expansion opportunities. These technologies are enhancing the identification of novel blood-based markers by enabling high-throughput screening and multi-dimensional data analysis. Omics-based insights are playing a crucial role in expanding the biomarker landscape and fostering the development of personalized diagnostics and treatment strategies tailored to individual patient profiles, as research continues to deepen the understanding of Parkinson’s disease pathology.
U.S. Blood-Based Biomarker for Parkinson’s Disease Market Report Highlights
In terms of application, the diagnostic biomarkers segment led revenue generation and was valued at USD 81.60 million in 2024, owing to their critical role in detecting Parkinson's during early/prodromal stages when intervention is most impactful.
Based on biomarker type, the NfL biomarker segment is projected to record the highest CAGR of 19.50% during the forecast period, owing to its established utility as a sensitive neurodegeneration indicator across multiple neurological disorders.
In terms of technology platform, the αSyn-SAA segment held a notable market share in 2024 due to its high sensitivity and specificity in detecting misfolded alpha-synuclein aggregates.
Based on end user, the pharmaceutical companies segment is projected to grow significantly during 2025–2034, driven by rising investments in disease-modifying therapies and personalized treatment development.
A few global key market players in the U.S. blood-based biomarker for Parkinson’s disease market include Abbott Laboratories, Alamar Biosciences, Amprion, Biogen, C2N Diagnostics, Denali Therapeutics, Quanterix Corporation, SomaLogic, Thermo Fisher Scientific Inc., and Verily Life Sciences
Polaris Market Research has segmented the U.S. blood-based biomarker for Parkinson’s disease market report on the basis of biomarker type, application, technology platform, and end user:
By Biomarker Type Outlook (Revenue, USD Million, 2020–2034)
Alpha-Synuclein (α-Syn)
Neurofilament Light Chain (NfL)
Inflammatory Markers
Metabolic Biomarkers
Others
By Application Outlook (Revenue, USD Million, 2020–2034)
Diagnostic Biomarkers
Prognostic Biomarkers
Monitoring Biomarkers
Therapeutic Response Biomarkers
Others
By Technology Platform Outlook (Revenue, USD Million, 2020–2034)
Alpha-Synuclein Seeding Amplification Assay (αSyn-SAA)
ELISA-Based Assays
Immunoassays
Mass Spectrometry
Others
By End User Outlook (Revenue, USD Million, 2020–2034)
Hospitals and Clinics
Diagnostic Laboratories
Research Institutes
Pharmaceutical Companies
Table of Contents
128 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
